Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
COLORADO SPRINGS, Colo., April 07, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release first quarter 2016 financial results after the market close on Thursday, April 28, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, April 28, 2016 to discuss results and provide a general business update.
The dial-in for the conference call is (877) 561-2747 for domestic callers or (973) 409-9689 for international callers. The Conference ID is 81186531. There will also be a live webcast of the call on the investor relations section of the Company’s website at www.spectranetics.com. The webcast will be available on the Company’s website for 14 days following the completion of the call.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 246-1713
